I. Hillebrand

414 total citations
20 papers, 293 citations indexed

About

I. Hillebrand is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Surgery. According to data from OpenAlex, I. Hillebrand has authored 20 papers receiving a total of 293 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Pharmacology and 4 papers in Surgery. Recurrent topics in I. Hillebrand's work include Natural Antidiabetic Agents Studies (11 papers), Diabetes Treatment and Management (10 papers) and Pharmacology and Obesity Treatment (7 papers). I. Hillebrand is often cited by papers focused on Natural Antidiabetic Agents Studies (11 papers), Diabetes Treatment and Management (10 papers) and Pharmacology and Obesity Treatment (7 papers). I. Hillebrand collaborates with scholars based in Germany, Belgium and United Kingdom. I. Hillebrand's co-authors include K. Boehme, H. Fink, Peter Berchtold, K.‐H. Graefe, J. Pichl, Erifili Hatziagelaki, Wolfram Domschke, Spiros D. Ladas, Jean‐Pierre Felber and Stephen R. Bloom and has published in prestigious journals such as Gastroenterology, Metabolism and Diabetic Medicine.

In The Last Decade

I. Hillebrand

19 papers receiving 268 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
I. Hillebrand Germany	9	192	83	66	63	54	20	293
Noboru Nakashima Japan	8	99 0.5×	185 2.2×	30 0.5×	26 0.4×	23 0.4×	15	462
Donald J. Walton Canada	8	188 1.0×	129 1.6×	17 0.3×	24 0.4×	90 1.7×	14	458
Shohei Hoshino Japan	6	120 0.6×	156 1.9×	33 0.5×	27 0.4×	45 0.8×	8	340
H. Fink Germany	7	101 0.5×	118 1.4×	46 0.7×	50 0.8×	58 1.1×	42	304
Ingo Tornus United States	6	148 0.8×	116 1.4×	16 0.2×	99 1.6×	14 0.3×	9	349
Stefan Bernbäck Sweden	6	87 0.5×	136 1.6×	161 2.4×	43 0.7×	83 1.5×	6	371
Tomoya Shintani Japan	10	200 1.0×	109 1.3×	35 0.5×	18 0.3×	105 1.9×	25	400
Joseph N. Pereira United States	10	75 0.4×	109 1.3×	23 0.3×	12 0.2×	89 1.6×	17	369
Sébastien Peltier France	10	51 0.3×	71 0.9×	54 0.8×	29 0.5×	104 1.9×	30	323
C.M. Wong Hong Kong	10	111 0.6×	65 0.8×	17 0.3×	19 0.3×	33 0.6×	16	369

Countries citing papers authored by I. Hillebrand

Since Specialization

Citations

This map shows the geographic impact of I. Hillebrand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Hillebrand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Hillebrand more than expected).

Fields of papers citing papers by I. Hillebrand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Hillebrand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Hillebrand. The network helps show where I. Hillebrand may publish in the future.

Co-authorship network of co-authors of I. Hillebrand

This figure shows the co-authorship network connecting the top 25 collaborators of I. Hillebrand. A scholar is included among the top collaborators of I. Hillebrand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Hillebrand. I. Hillebrand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schöffling, Κ. & I. Hillebrand. (2008). Acarbose - ein neues therapeutisches Prinzip in der Behandlung des Diabetes mellitus. DMW - Deutsche Medizinische Wochenschrift. 106(35). 1083–1084.

Ruppin, H, et al.. (1988). Fate and effects of the α-glucosidase inhibitor acarbose in humans. Gastroenterology. 95(1). 93–99. 5 indexed citations

Ruppin, H, et al.. (1988). Fate and effects of the α-glucosidase inhibitor acarbose in humans. Gastroenterology. 95(1). 93–99. 16 indexed citations

Dimitriadis, George, Erifili Hatziagelaki, Spiros D. Ladas, et al.. (1988). Effects of prolonged administration of two new α‐glucosidase inhibitors on blood glucose control, insulin requirements and breath hydrogen excretion in patients with insulin‐dependent diabetes mellitus. European Journal of Clinical Investigation. 18(1). 33–38. 10 indexed citations

Serrano‐Ríos, Manuel, et al.. (1988). Effect of two new α-glucosidase inhibitors in insulin-dependent diabetic patients. Diabetes Research and Clinical Practice. 4(2). 111–116. 3 indexed citations

Laube, H., K. Federlin, & I. Hillebrand. (1988). Effect of Alpha-Inhibitors on Blood Glucose and Insulin Levels. Advances in experimental medicine and biology. 246. 287–295. 1 indexed citations

Bottorff, Michael B., William E. Evans, I. Hillebrand, et al.. (1988). Drug Concentration Monitoring Microbial Alpha-Glucosidase Inhibitors Plasminogen Activators. 1 indexed citations

Hillebrand, I.. (1987). Pharmacological Modification of Digestion and Absorption. Diabetic Medicine. 4(2). 147–150. 5 indexed citations

Federlin, K., LUDWIG MEHLBURGER, I. Hillebrand, & H. Laube. (1987). The effect of two new glucosidase inhibitors on blood glucose in healthy volunteers and in type II diabetics. Acta Diabetologica. 24(3). 213–221. 6 indexed citations

10.

Hillebrand, I., et al.. (1987). The clinical efficacy of a second-generation alpha-glucosidase inhibitor in non-insulin-dependent diabetic patients.. PubMed. 71(7). 422–3. 2 indexed citations

11.

Gérard, Jean‐Louis, et al.. (1987). Assessment of the clinical efficacy and tolerance of two new alpha-glucosidase inhibitors in insulin-treated diabetics.. PubMed. 25(9). 483–8. 1 indexed citations

12.

Katsilambros, Nicholas, et al.. (1986). A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type-2 diabetics.. PubMed. 36(7). 1136–8. 20 indexed citations

13.

Hillebrand, I., et al.. (1986). The effect of newα-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man. Journal of Molecular Medicine. 64(8). 393–396. 23 indexed citations

14.

Gent, C.M. van, et al.. (1986). Long-term effect of acarbose on diurnal serum triglyceride, glucose, insulin and adipose tissue lipoprotein lipase levels in patients with primary endogenous hypertriglyceridaemia, with or without type II diabetes.. PubMed. 29(5). 157–64. 4 indexed citations

15.

Cauderay, Michel, Luc Tappy, E Temler, et al.. (1986). Effect of α-glycohydrolase inhibitors (Bay m1099 and Bay o1248) on sucrose metabolism in normal men. Metabolism. 35(5). 472–477. 18 indexed citations

16.

Dimitriadis, George, S. Raptis, Athanasios Raptis, et al.. (1986). Effects of two new α-glucosidase inhibitors on glycemic control in patients with insulin-dependent diabetes mellitus. Journal of Molecular Medicine. 64(9). 405–410. 11 indexed citations

17.

Hillebrand, I., et al.. (1985). The effect of a 1-deoxynojirimycin derivative on post-prandial blood glucose and insulin levels in healthy black and white volunteers. European Journal of Clinical Pharmacology. 28(6). 705–708. 21 indexed citations

18.

Buysschaert, Martin, et al.. (1983). Effect of Acarbose on Blood Glucose Profile of Totally Insulin-Dependent Diabetic Patients. Acta Clinica Belgica. 38(1). 5–11. 5 indexed citations

19.

Hillebrand, I., et al.. (1979). The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: Dose-time-response relationships in man. Research in Experimental Medicine. 175(1). 87–94. 51 indexed citations

20.

Hillebrand, I., et al.. (1979). The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man. Research in Experimental Medicine. 175(1). 81–86. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact